Drawing for Serial No. 87784088

USPTO serial 87784088

Serial No. 87784088

Reviewed by CopyMark Law Group

Reg. 5803109Status 702Registered
Filing date
Status date
Registration date
Jul 16, 2019
Examiner
SCHMIDT, JOHN JOSEPH
Law office
Historical data usage

What this means

Status 702 means the registration is active, Section 8 was accepted, and a Section 15 declaration of incontestability was also accepted. Incontestability strengthens your rights by limiting certain challenges after five years of continuous use. Continue use in commerce and plan for the 10-year Section 8 and 9 renewal.

Status 702: Status 702 means the registration is active, Section 8 was accepted, and a Section 15 declaration of incontestability was also accepted. Incontestability strengthens your rights by limiting certain challenges after five years of continuous use.

Need help with Serial No. 87784088?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Daniel M. Gurfinkel

Daniel M. Gurfinkel Dennemeyer & Associates, LLC230 W. Monroe St.Suite 2100Chicago, IL 60606

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations in the field of human medicine, namely, anti-acid medications, anti-anxiety drugs, antibiotics, antidepressants, antihistamines, drugs for the prevention and treatment of symptoms of menopause and estrogen deficiency, antipsychotics, blood disorder drugs in the nature of a blood clotting aid, cancer drugs for the prevention and treatment of cancer, decongestants, expectorants, fertility drugs in the nature of fertility enhancement preparations, heart drugs for the treatment of heart rhythm disorders, metabolic drugs to lower cholesterol, control diabetes and regulate thyroid hormones, nervous disorder drugs for the treatment of disorders of the nervous system, ophthalmic drugs for the treatment of ophthalmic disorders, and stomach and bowel problem drugs for the treatment of stomach and bowel disordersACTIVEJul 1, 2002

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Nov 6, 2025NA85NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED—
Nov 6, 2025C15AREGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.—
Nov 6, 2025APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Jul 16, 2025E815TEAS SECTION 8 & 15 RECEIVED—
Jul 16, 2024REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
Jul 16, 2019R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Jul 8, 2019DOCKASSIGNED TO EXAMINER—
Apr 30, 2019NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Apr 30, 2019PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Apr 10, 2019NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Mar 19, 2019CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Mar 19, 2019XAECEXAMINER'S AMENDMENT ENTERED—
Mar 19, 2019GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Mar 19, 2019GNEAEXAMINERS AMENDMENT E-MAILED—
Mar 19, 2019CNEAEXAMINERS AMENDMENT -WRITTEN—
Mar 14, 2019TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Mar 13, 2019TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Mar 13, 2019CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Mar 13, 2019ERFRTEAS REQUEST FOR RECONSIDERATION RECEIVED—
Mar 13, 2019ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Mar 13, 2019REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Nov 20, 2018GNFNNOTIFICATION OF FINAL REFUSAL EMAILED—
Nov 20, 2018GNFRFINAL REFUSAL E-MAILEDA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Nov 20, 2018CNFRFINAL REFUSAL WRITTENA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Oct 31, 2018TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Oct 31, 2018CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Oct 18, 2018ALIEASSIGNED TO LIE—
Oct 9, 2018TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
May 25, 2018GPRNNOTIFICATION OF PRIORITY ACTION E-MAILEDA priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline.
May 25, 2018GPRAPRIORITY ACTION E-MAILEDA priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline.
May 25, 2018CPRAPRIORITY ACTION WRITTENA priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline.
May 18, 2018DOCKASSIGNED TO EXAMINER—
Feb 14, 2018MDSCNOTICE OF DESIGN SEARCH CODE E-MAILED—
Feb 13, 2018NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Feb 8, 2018NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance